Fate Therapeutics Appoints AI Expert to Enhance Board
PremiumCompany AnnouncementsFate Therapeutics Appoints AI Expert to Enhance Board
2M ago
Fate Therapeutics appoints Neely Mozaffarian to board of directors
Premium
The Fly
Fate Therapeutics appoints Neely Mozaffarian to board of directors
2M ago
FATE Earnings this Week: How Will it Perform?
Premium
Pre-Earnings
FATE Earnings this Week: How Will it Perform?
2M ago
Fate Therapeutics upgraded to Overweight from Neutral at Piper Sandler
PremiumThe FlyFate Therapeutics upgraded to Overweight from Neutral at Piper Sandler
3M ago
Fate Therapeutics Announces CFO Change and Shareholder Approvals
Premium
Company Announcements
Fate Therapeutics Announces CFO Change and Shareholder Approvals
3M ago
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Premium
Press Releases
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
4M ago
Fate Therapeutics price target lowered to $4 from $7 at Piper Sandler
PremiumThe FlyFate Therapeutics price target lowered to $4 from $7 at Piper Sandler
4M ago
Fate Therapeutics price target lowered to $5 from $7 at Wedbush
Premium
The Fly
Fate Therapeutics price target lowered to $5 from $7 at Wedbush
4M ago
Fate Therapeutics price target lowered to $9 from $11 at Canaccord
Premium
The Fly
Fate Therapeutics price target lowered to $9 from $11 at Canaccord
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100